

# ACL Laboratories COVID-19 and Influenza Activity Report

Updated: Apr 25, 2021




## Respiratory Pathogens - Apr 25, 2021

Week	InfA-H1	InfA-H3	2009 H1N1	Inf B	RSV	Para-influenza	EV/Rhino	Meta pneumo	Adeno virus	Corona viruses	Bocca	Myc. pneumo	Chlam. pneumo.	Leg. pneumo.	BP / BPP	Total Pos	POS FLU	Total	ACL RPPNL	CDC US %FLU	CDC IL/WI %FLU	ACL FLUPCR
Apr 25	0	0	0	0	0	2	30	2	3	13	3	0	0	0	0	53	0	191	0.0	n/a	n/a	0.0
Apr 18	0	0	0	0	1	1	23	3	0	5	1	0	0	0	0	33	0	213	0.0	<0.1	<0.1	0.0
Apr 11	0	0	0	0	0	2	30	0	4	11	3	0	0	0	0	33	0	187	0.0	<0.1	<0.1	0.0
Apr 4	0	0	0	0	0	2	19	0	3	8	1	0	0	0	0	33	0	146	0.0	<0.1	<0.1	0.0
Mar 28	0	0	0	0	0	0	21	1	2	6	0	0	0	0	0	30	0	197	0.0	0.1	0.1	0.0
Mar 21	0	0	0	0	0	0	28	0	3	5	1	0	0	0	0	34	0	172	0.0	0.1	0.0	0.0
Mar 12	0	0	0	0	0	0	22	0	1	1	0	0	0	0	0	24	0	153	0.0	0.1	0.1	0.0
Mar 7	0	0	0	0	0	0	15	1	1	1	0	0	0	0	0	18	0	127	0.0	0.2	0.2	0.0
Feb 28	0	0	0	0	1	0	3	0	1	1	0	0	0	0	0	6	0	148	0.0	0.1	0.2	0.0
Feb 21	0	0	0	0	0	0	9	0	0	1	0	0	0	0	0	10	0	135	0.0	0.2	0.1	0.0
Feb 14	0	0	0	0	0	0	12	0	0	1	0	0	0	0	0	13	0	140	0.0	0.1	0.1	0.0
Feb 7	0	0	0	0	0	0	10	1	0	1	1	0	0	0	0	12	0	143	0.0	0.1	0.1	0.0

Increased prevalence of **Rhinovirus** and **Corona NL63** and **Corona OC43** (see column in red)

# ACL RESP. PANEL - POS Rate Selected viruses Apr 25, 2021

- EV / Rhino
- Para- influenza
- Corona viruses
- Adeno virus
- Meta pneumo




SARS-COV-2					RSV - no activity				Influenza - no activity			
Week	IL % SCVPCR	WI % SCVPCR	IL % COVAG	WI % COVAG	IL % RSVPCR	WI % RSVPCR	IL % RSVAG	WI % RSVAG	IL % FLUPCR	WI % FLUPCR	IL % FLUAG	WI % FLUAG
Apr 25	7.8	3.7	9.3	15.3	0	0	0	0	0	0	0	3
Apr 18	8.0	4.1	10.6	14.0	0	0	0	0	0	0	0	3
Apr 11	6.5	3.9	12.3	11.9	0	0	0	0	0	0	0	3
Apr 4	5.5	3.6	10.4	10.2	0	0	0	0	0	0	0	3
Mar 28	5.0	3.1	10.5	10.1	0	0	0	0	0	0	0	0
Mar 21	3.9	2.1	6.8	8.7	0	0	0	0	0	0	0	2
Mar 12	2.9	2.0	8.3	5.8	0	0	0	0	0	0	0	0
Mar 7	3.2	2.4	8.0	5.5	0	0	1	0	0	0	0	2
Feb 28	3.1	2.3	6.3	4.8	0	0	1	0	0	0	0	1.5
Feb 21	4.3	2.6	9.6	7.7	0	0	0	0	0	0	0	1.5
Feb 14	4.7	2.7	7.6	11.3	0	0	0	0	0	0	n/a	2


**COVAG Antigen rapid test** – is performed at **Urgent Care** sites  
– **WI sites are detecting higher rates of COVAG**

## ACL COVAG and SCVPCR - Pos rate (%) - Apr 25, 2021


- IL % COVAG
- WI % COVAG
- IL % SCVPCR
- WI % SCVPCR



# Apr 25, 2021 - daily COVID-19 cases in US - CDC



# Apr 20, 2021 – SARS-CoV-2 variants circulating in the US (~60% is UK variant)



## Vaccination status CDC | Data as of: Apr 22, 2021

**218,947,643**

**Vaccines Administered**

**135,791,031**

**People who received  
at least one dose**

**89,245,776**

**People who are fully  
vaccinated\***

**40.9%**


**Percentage of the US  
population that has  
received at least one  
dose**

**26.9%**

**Percentage of the US  
population that has  
been fully vaccinated\***





# Influenza Positive Tests Reported to CDC by U.S. Clinical Laboratories, National Summary, September 27, 2020 – April 17, 2021




2020-21 Influenza Season Week 15 ending Apr 17, 2021

ILI Activity Level




## Percent of Respiratory Specimens Positive for Flu


2017-18 2018-19 2019-20 2020-21




# CSF targets positivity rate is 6%



# The most prevalent GI bacterial targets (*E. histolytica*)



# The most prevalent GI viral targets – Norovirus 1.5%



Women's Health - Apr 27, 2021 positivity rate (%)				
Bacterial Vag.	Candida spp.	Candida glab.	Trich. vag	M. genitalium
27	21	2	2	9

